Trial Profile
A Phase II, randomized, double-blind, placebo-controlled multi-site study of Leukine (Sargramostim) in Parkinson's Disease
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 25 May 2021
Price :
$35
*
At a glance
- Drugs Sargramostim (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- 25 May 2021 New trial record
- 19 May 2021 According to a Partner Therapeutics media release, the company is planning to submit an IND application for the initiation of this study.